Abstract
We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. Of 7,950 samples, 8 were positive by both assays. Using 2 reliable antibody tests in conjunction is an effective method for estimating seroprevalence in low prevalence settings.
Highlights
We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020
We used 2 serologic tests, a neutralizing antibody assay, and participant questionnaires to estimate the seroprevalence of SARS-CoV-2 infection in Japan
The Tokyo metropolitan government used random sampling stratified by age and sex in 3 cities with a cumulative incidence resembling the average of the Tokyo metropolitan area
Summary
We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. The Study By October 2020, no standard antibody test or standardized method for estimating the seroprevalence of SARS-CoV-2 infection had been established. We used 2 serologic tests, a neutralizing antibody assay, and participant questionnaires to estimate the seroprevalence of SARS-CoV-2 infection in Japan. To better estimate the range of seroprevalence of SARS-CoV-2 infection in Japan, we chose a prefecture with a relatively low cumulative incidence, Miyagi, with an incidence of 0.004% (88 cases/2.3 million population).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.